Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
CureApp Files Therapeutic App for Hypertension in Japan, Eyes Launch in 2022
Tokyo-based health tech CureApp has filed its digital therapeutic app for hypertension, seeking its regulatory approval as software as a medical device (SaMD), President Kota Satake revealed on September 3. The company is looking at its launch in 2022. “We…
To read the full story
Related Article
- Teijin to Copromote CureApp’s Hypertension Therapy App
April 24, 2024
- Hypertension Therapy App Might Reduce Use of Antihypertensives: CureApp
April 10, 2024
- CureApp’s Hypertension Therapeutic App Shows Effects in Clinical Setting
September 27, 2023
- CureApp’s Hypertension Therapeutic App Rolls Out with Insurance Coverage
September 2, 2022
- Chuikyo OKs Insurance Coverage for CureApp’s Hypertension Therapeutic App
August 5, 2022
- CureApp Wins Japan Nod for Hypertension Therapeutic App, Eyes 2022 Rollout
April 28, 2022
- Therapeutic App for Hypertension Now in Line for April Approval
March 10, 2022
- Therapeutic App for Hypertension Up for PAFSC Review on March 9
February 24, 2022
- CureApp Hypertension Therapeutic App Hits PIII Goal, 2021 Submission Eyed
March 17, 2021
- Japan’s 1st Therapeutic App Now Available: CureApp
December 2, 2020
- CureApp to File Hypertension Treatment App as Early as 2021, PIII Trial Now Underway
February 3, 2020
BUSINESS
- Lilly to Invest Additional 20 Billion Yen in Japan's Seishin Plant
March 13, 2026
- Half of Drug Makers Reluctantly Support G1 Rule Overhaul: Jiho Survey
March 12, 2026
- FDA Resumes Review of Capricor/Nippon Shinyaku’s DMD Cell Therapy
March 12, 2026
- Hisamitsu Starts Promotion of Yaz AGs under Bayer Alliance
March 11, 2026
- Seagen ADC Patent Dispute Ends with Daiichi Sankyo Victory
March 11, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…